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Abstract
Background: There is no established biochemical basis for the neurotoxicity of mefloquine. We
investigated the possibility that the acute in vitro neurotoxicity of mefloquine might be mediated
through a disruptive effect of the drug on endoplasmic reticulum (ER) calcium homeostasis.
Methods: Laser scanning confocal microscopy was employed to monitor real-time changes in
basal intracellular calcium concentrations in embryonic rat neurons in response to mefloquine and
thapsigargin (a known inhibitor of the ER calcium pump) in the presence and absence of external
calcium. Changes in the transcriptional regulation of known ER stress response genes in neurons
by mefloquine were investigated using Affymetrix arrays. The MTT assay was employed to measure
the acute neurotoxicity of mefloquine and its antagonisation by thapsigargin.
Results: At physiologically relevant concentrations mefloquine was found to mobilize neuronal ER
calcium stores and antagonize the pharmacological action of thapsigargin, a specific inhibitor of the
ER calcium pump. Mefloquine also induced a sustained influx of extra-neuronal calcium via an
unknown mechanism. The transcription of key ER proteins including GADD153, PERK, GRP78,
PDI, GRP94 and calreticulin were up-regulated by mefloquine, suggesting that the drug induced an
ER stress response. These effects appear to be related, in terms of dose effect and kinetics of
action, to the acute neurotoxicity of the drug in vitro.
Conclusions: Mefloquine was found to disrupt neuronal calcium homeostasis and induce an ER
stress response at physiologically relevant concentrations, effects that may contribute, at least in
part, to the neurotoxicity of the drug in vitro.
Background
Mefloquine is a prophylactic antimalarial drug that is also
used for malaria chemotherapy. Adverse central nervous
system (CNS) events have been associated with its use
[1,2]. Severe CNS events requiring hospitalization occur
in 1:10,000 and 1:200–1200 patients taking mefloquine
for chemoprophylaxis or treatment, respectively [1,2].
Milder CNS events (e.g. dizziness, headache and insom-
nia) are a more frequent occurrence, being experienced by
up to 25% of patients receiving chemoprophylactic doses
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and 90% of those receiving therapeutic doses [1,2].
Higher blood levels of mefloquine are reached under ther-
apeutic regimens (2.1–23 µM) compared with those for
prophylaxis (3.8 µM) [3,4]. The relative incidence of
adverse effects is, therefore, probably dose-related,
although the concomitant effect of malaria during treat-
ment cannot be dismissed. It is likely, then, that the
adverse neurological events associated with mefloquine
have a biochemical basis.
To date, no satisfactory biochemical explanation of the
neurotoxicity of mefloquine has been proposed. How-
ever, two lines of evidence suggest that the endoplasmic
reticulum might be a neuronal target of mefloquine. Go
and others [5,6] showed that mefloquine affects calcium
flux into and out of isolated mammalian microsomes
obtained from skeletal muscle and neuronal tissue. These
observations suggest that mefloquine might disrupt ER
calcium homeostasis, but are difficult to interpret since
the experiments were not conducted in an intact cell sys-
tem. In an unrelated study, we investigated the effects of
mefloquine on global transcription in rat neuroblastoma
(NG108) cells using microarrays [7]. Mefloquine caused a
striking upregulation of growth arrest and development
protein 153 (GADD153), a transcription factor selectively
modulated under conditions of ER stress [8]. Taken
together, these observations suggest that mefloquine
might perturb the function of the ER via a disruption of
calcium homeostasis. Most ER-active agents (e.g. thapsi-
gargin and ryanodine) deplete the ER calcium pool either
by (i) inhibiting the ER calcium pump and thereby pre-
venting the replenishment of the ER calcium pool or (ii)
triggering ER (ryanodine or inositol 1,4,5-trisphosphate
(IP3) activated) calcium release channels [9]. These phe-
nomena can be visualized by fluorescence microscopy as
a transient increase in cytoplasmic calcium concentrations
(for example see [10]). Nominally calcium-free media are
used so that the effect can be distinguished from calcium
influx mediated via plasma membrane channels. If the
test agent can be shown to antagonize the release of cal-
cium by a known ER agonist, it can then be concluded that
the ER calcium pool is a target of the compound.
ER function is critical if protein synthesis and folding is to
successfully occur in eukaryotic cells [11,12]. ER stress,
induced by cellular events as diverse as disrupted calcium
homeostasis, elevated levels of reactive oxygen species
and viral infection, leads to accumulation of dysfunc-
tional ER chaperones and misfolded proteins [11]. Cells
respond by one or both of two conserved stress response
pathways. The first, the ER overload response, triggers the
activation of the transcription factor NFkB and the subse-
quent upregulation of inflammatory proteins [13]. The
second, the unfolded protein response (UPR) induces
three divergent cellular events: (i) the activation of tran-
scription factor ATF6 leading to the upregulation of ER
chaperones such as protein disulfide isomerase, (ii)
upregulation of the pro-apoptotic transcription factor
GADD153 and (iii) suppression of protein synthesis via
phosphorylation of eukaryotic translation initiation fac-
tor 2α (eIF2α) by pancreatic eIF2α kinase (PEK/PERK,
[11,12]). Upregulation of the ER chaperones, GADD153
and PERK in response to a toxic insult would constitute
direct evidence of an ER stress response.
In the present study, using laser scanning confocal micro-
scopy, we show that the ER calcium pool is a target of
mefloquine in rat neurons, as, under calcium free condi-
tions, the drug induces elevations in intracellular calcium
concentrations and antagonizes the pharmacological
effect of thapsigargin, a known inhibitor of the ER calcium
pump. Further, we show that, in the presence of extra-neu-
ronal calcium, mefloquine induces a sustained elevation
of cytoplasmic calcium levels via an unknown mecha-
nism. The disruption of calcium homeostasis by meflo-
quine appears to be related, in terms of dose-effect and
kinetics of action, to the acute neurotoxicity of the drug.
In a microarray study we also show that mefloquine
induces the transcription of key ER stress response genes.
Collectively, the data suggest that mefloquine may inhibit
neuronal ER function and disrupt neuronal calcium
homeostasis at physiologically relevant concentrations in
vitro.
Methods
Materials
Racemic (erythro) mefloquine was obtained from the
WRAIR chemical inventory system. The calcium-sensitive
dye Fluo3 was purchased from Molecular Probes, Eugene,
OR. Reagents used in cell culture and neurotoxicity/neu-
roprotection assays were obtained from Sigma, St Louis,
MO. Biosource International, Rockville, MD, and GIBCO/
Life Technologies, Grand Island, NY.
Preparation of primary neuronal cell cultures
Primary neuronal cultures of feotal rat forebrains were
prepared as described previously [14]. Briefly, the fore-
brains of feotal rat pups (embryonic day 15) were iso-
lated, and the cells were dispersed by repeated mechanical
trituration in neuronal culture medium (NCM = Ham's F-
12: Basal Medium Eagle, 1:1; supplemented with dex-
trose, 0.6 g/l; glutamine, 0.35%; and Pen-Strep, 1%). Fol-
lowing centrifugation (900 × g; 5 min) and re-suspension
in fresh NCM, the cells were counted and plated onto
poly-L-lysine-coated 48 well plates at a density of 0.5 ×
106 cells/well. For imaging experiments the neurons were
transferred to 4-chamber cover glass slides that had been
previously coated with poly-L-lysine followed by colla-
gen. Each chamber contained 1 × 106 cells. For the array
studies, the neurons (20 × 106 neurons per flask) wereMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
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transferred to 75 cm2 flasks. To suppress glial growth, cul-
tures were treated with cytosine β-D-arabinofuranoside
(10-5 M) after 3 days in vitro. All cultures were maintained
in an incubator (5% CO2; 37°C) for at least 6 days and no
more than 10 days prior to use.
Confocal microscopy
The approach utilized for confocal microscopy experi-
ments is similar to that employed in an earlier study [14].
Neurons (on chamber slides) were treated with 5 µM
Fluo-3-AM for 1 h. After 1 h in an incubator, the cells were
rinsed with fresh Mg2+-free Locke's solution (NaCl, 154
mM; KCl, 5.6 mM; NaHCO3, 3.6 mM; CaCl2, 2.3 mM; glu-
cose, 5.6 mM; HEPES, 5 mM; pH 7.4), and returned to the
incubator for an additional 15 minutes prior to initiating
the imaging experiments. Changes in neuronal calcium
homeostasis were monitored using a Bio-Rad Radiance
2000 confocal imaging system. Changes in cytoplasmic
calcium were recorded as fluctuations in the emitted fluo-
rescence of Fluo-3-complexed calcium at 530 nm (excita-
tion was 488 nm). Sequential image scans of fields
containing 5–25 neurons were used to construct temporal
profiles of the effects of the different agonists. Typically,
scans were made at 10 or 15 s intervals. To compare the
fluorescence levels in different neurons (which were often
in slightly different focal planes) on different days, the flu-
orescence readings at each time point were normalized to
the first one taken for each neuron.
Effects of mefloquine on ER calcium homeostasis
In the first series of experiments, mefloquine's effects on
mobilization of ER calcium stores were investigated. The
neurons (chamber slides) were rinsed twice with fresh low
calcium Locke's buffer (NaCl, 154 mM; KCl, 5.6 mM;
NaHCO3, 3.6 mM; CaCl2, 0.92 mM; glucose, 5.6 mM;
HEPES, 5 mM; EGTA, 1 mM; pH 7.4) and immersed in the
same solution (240 µl per chamber). Neurons were
scanned at 10 s intervals. Mefloquine (final concentration
of 80 µM) or DMSO (0.2%), thapsigargin (1 µM), gluta-
mate (1 µM) and CaCl2 (1.6 mM), were added after scans
3, 33, 63 and 67 respectively. All drugs were prepared in
calcium-free Locke's solution containing no EGTA. Data
analysis was conducted only for neurons in which an
increase in cytoplasmic calcium was observed after the
addition of calcium chloride.
Effects of lower mefloquine doses on ER calcium 
homeostasis
In a second series of experiments, the effects of lower
mefloquine doses on ER calcium homeostasis were inves-
tigated. The neurons (chamber slides) were rinsed twice
with fresh low calcium Locke's buffer containing DMSO
(NaCl, 154 mM; KCl, 5.6 mM; NaHCO3, 3.6 mM; CaCl2,
0.92 mM; glucose, 5.6 mM; HEPES, 5 mM; EGTA, 1 mM;
DMSO, 0.625%; pH 7.4) and immersed in the same solu-
tion (240 µl per chamber). Neurons were scanned at 10 s
intervals. Mefloquine (2, 10, 30, 60, 80 or 200 µM), thap-
sigargin (1 µM), glutamate (1 µM) and CaCl2 (1.6 mM
final concentration) were added sequentially as outlined
earlier, except that for the lowest mefloquine dose experi-
ment, 2 and 10 µM mefloquine were added to the same
well after scans 3 and 18 respectively. Selection of neurons
for data analysis was conducted as described above. For
each mefloquine concentration in each experiment, the
maximum increase in the cytoplasmic calcium concentra-
tion relative to the baseline was determined (at least four
replicate experiments were conducted for each meflo-
quine concentration). For example, the maximum relative
increase in cytoplasmic calcium concentration induced by
mefloquine at 80 µM in one of the experiments was 2.95,
as illustrated in Figure 1. Concentration-response effects
were then expressed as a percentage change in terms of the
mean relative increase in cytoplasmic calcium observed at
the highest mefloquine concentration. The highest meflo-
quine concentration used was 200 µM, since this was the
lowest concentration tested that induced almost 100%
loss of viability after five minutes exposure (Figure 3).
Effect of mefloquine on cytoplasmic calcium homeostasis 
and its antagonisation by thapsigargin
The effect of mefloquine on whole cell calcium homeos-
tasis was also investigated. The neurons (chamber slides)
were rinsed twice with fresh Locke's buffer containing
physiological levels of calcium (NaCl, 154 mM; KCl, 5.6
mM; NaHCO3, 3.6 mM; CaCl2, 2.3 mM; glucose, 5.6 mM;
HEPES, 5 mM; pH 7.4) and immersed in the same solu-
tion (240 µl per chamber). Neurons were scanned at 15 s
intervals. Mefloquine (80 µM), thapsigargin (4 µM) or
DMSO (0.4%) were added after scan 13 and DMSO
(0.2%) or mefloquine (80 µM) after scan 28.
Detection of transcriptional changes in key ER stress 
response genes using microarrays
Neurons (75 cm2 culture flasks) were treated with 0.2%
DMSO (controls), 2, 10 or 80 µM mefloquine in Locke's
buffer (containing calcium) for five minutes. This treat-
ment time was chosen because the depletion of the ER cal-
cium store by mefloquine occurs within this time period.
After 5 min, the media were replaced with MEM contain-
ing 0.02% DMSO (for the control, 10 and 80 µM meflo-
quine treatment groups) or 2 µM mefloquine for a further
24 h. Therefore, neurons were exposed to the lowest
mefloquine concentration for 24 h. A recovery period of
24 h is required following an insult with an ER-agonist to
induce a maximal ER stress response [8]. After 24 h, total
RNA was extracted from the flasks using RNA-STAT 60 as
previously described [7]. The experiment was repeated
five times on independent occasions.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
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Detailed procedures for preparation of cDNA and fluores-
cently labeled cRNA, hybridization, staining, and scan-
ning of gene chips and assay monitoring are outlined in
earlier literature [15]. The platform chosen for global
expression profile was the Rat Genome U34 Array
(Affymetrix, Santa Clara, California), which contains
probes for a total of 8799 expressed sequence tag (EST)
clusters and genes (including controls). RNA (10 µg)
extracted from each individual flask was hybridized to a
single gene chip (i.e. a total of 20 chips were used).
Affymetrix analysis software (version 5) was used to gen-
erate average difference (AD) values for each gene for each
treatment (Affymetrix, Santa Clara, California). AD values
represent the difference in mean fluorescence between
positive and mismatch probe cells for each gene, and are
hereafter referred to as expression values.
The Affymetrix website http://www.affymetrix.com was
searched using the terms 'PEK/PERK', 'GADD153' and the
gene names for ER chaperones previously identified as
being upregulated during an ER stress response [12], and
where they were represented by probe-sets on the U34
Figure 1
Effects of mefloquine on ER calcium homeostasis. The effects of mefloquine on cytoplasmic calcium levels in rat neu-
rons were investigated using confocal microscopy. Neurons were loaded with the calcium-sensitive dye Fluo-3 that was 
replaced with low-calcium Locke's buffer after 1 h. The neurons were scanned at 10 s intervals to measure baseline fluores-
cence prior to the addition of DMSO (0.2%) or mefloquine (Mef, 80 µM) followed by thapsigargin (Thaps, 1 µM). Arrows indi-
cate additions after scans 2 and 37, respectively. Mefloquine increased cytoplasmic calcium and antagonized the 
pharmacological action of thapsigargin, suggesting that the drug mobilizes the ER calcium store. The lack of a subsequent gluta-
mate response (Glu, 1 µM after scan 63) demonstrates the external medium was substantially devoid of free calcium, whilst the 
presence of a subsequent CaCl2 (1.6 mM after scan 67) response indicates that the neurons remain viable at the termination of 
the experiment.
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arrays, corresponding accession numbers were identified.
The expression values for these accession numbers were
imported directly into Parteck Pro 2000. No additional
data normalization or scaling methods were employed (as
these procedures were performed previously by the
Affymetrix software). One-way ANOVAs were performed
to compare the mean expression levels of each of the
genes amongst the different treatment groups. A signifi-
cant change in mean expression level was assumed to have
occurred where ANOVA P-values were < 0.05. A less con-
servative significance threshold was considered appropri-
ate since the total number of hypotheses (i.e. tests of
significance) conducted was small. For a particular treat-
ment group, a gene was considered to have differentially
modulated expression where the fold-change in expres-
sion exceeded 1.3. Fold-changes (FC) in expression were
defined as: = mean mefloquine expression level/mean
DMSO expression level. Where a gene was represented by
Figure 2
Effects of low calcium Locke's buffer on neuronal viability. Neurons were exposed to MEM (controls), Locke's buffer 
with and without Ca2+ and/or 1 mM EGTA for 15 min or to a low calcium Locke's buffer (LCLB) containing 920 µM Ca2+ and 1 
mM EGTA for 2.5, 5, 7.5, 10, 12.5 and 15 min. Viability was assessed using the colorimetric MTT assay, where a loss of viability 
is reflected in a decrease in absorbance at λ = 540 (A540). The substitution of normal Locke's buffer for one containing no 
added calcium results in a loss of neuronal viability (27%, Welch's test, P < 0.005, n = 8, indicated by a superscript a). This solu-
tion was not used for the mefloquine studies because control experiments showed that glutamate elicited a calcium response 
in neurons exposed to this buffer, presumably because the rinsing procedure did not remove all residual free calcium. A 10 min 
exposure to LCLB was required to reduce viability below that of the calcium-free Locke's buffer (one way ANOVA and Dun-
nett's test, P < 0.05, n = 44, * designates a significant change). Use of this buffer does not elicit a glutamate response, and there-
fore should not contain substantial amounts of free calcium. Experiments that utilized this buffer to investigate the effect of 
mefloquine on neuronal calcium homeostasis were performed within this ten-minute window.
0.00
0.25
0.50
0.75
Control (MEM)
Locke's
Locke's - CA
Locke's + EGTA
LCLB-2.5 min
LCLB-5 min
LCLB-7.5 min
LCLB-10 min
LCLB-12.5 min
LCLB-15 min
Locke's - CA + EGTA
* *
*
*
*
*
*
A
5
4
0
aMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
Page 6 of 14
(page number not for citation purposes)
more than one probe set, data is presented only for those
probe-sets for which the ANOVA P-value was < 0.05.
Viability measurements
Neuronal viability was assessed using the colorimetric
MTT assay as described previously [14]. All experiments
were conducted in Mg2+-free Locke's solution unless oth-
erwise indicated. Neurons were exposed to graded con-
centrations of mefloquine for 5 or 20 min and 24 h. After
treatment, mefloquine dilutions were removed and
replaced with MEM (Gibco). The neurons were incubated
for a further 24 h. The next day MTT was added to each
well such that the final concentration of the dye was 150
µg/ml. Plates were then returned to the incubator for 1 h
at which time unincorporated MTT was removed, and the
plates were allowed to air dry. The purple formazan prod-
uct indicative of viable cells was then dissolved by adding
250 µl acidified isopropanol (95% isopropanol; 5% 2N
Figure 3
Dose-response curves for mefloquine's effects on neuronal cell viability and mobilization of ER calcium stores. 
Neurons were exposed to mefloquine (0.75–200 µM) for 5 min, 20 min or 24 h. Viability was assessed using the colorimetric 
MTT assay. Dose-response data is presented as mean viability (% ± SEM compared to appropriate DMSO controls) and repre-
sents data from at least three pooled experiments. For the ER-calcium experiments, changes in neuronal intracellular calcium 
concentrations induced in response to different mefloquine treatments were monitored in real time using confocal micros-
copy. Dose-response effects are expressed as a percentage of the maximal elevation of cytoplasmic calcium occurring at 200 
µM mefloquine. The dose-response curves for mefloquine's effects on neuronal viability (5 min exposure) and ER calcium store 
mobilization are superimposable, as are the 20 min and 24 h exposure curves. At a concentration of 50 µM, mefloquine exhib-
ited greater toxicity after 20 min and 24 h exposure as compared to 5 min exposure (one way ANOVA and Dunnett's t-test, P 
< 0.0001, n = 12, see asterixed points on graph). Therefore, it appears that the neurotoxic effects of mefloquine occur within 
20 min of exposure, but cannot be accounted for solely by the disruptive effect of mefloquine on ER calcium homeostasis.
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HCl), and 200 µl aliquots were collected. The absorbance
of these aliquots was measured on an ELISA plate reader
at 540 nm. The effects of mefloquine were compared to
appropriate DMSO controls.
The acute toxicity of the low calcium Locke's solution was
also investigated. Neurons were exposed to the buffer at
2.5 minute intervals over a 15 min time period. Effects of
the various treatments were compared to appropriate con-
trols (Locke's solution with and without calcium and/or 1
mM EGTA for 15 minutes). Viability was assessed as
above except that the neurons were not incubated over-
night in MEM prior to performing the MTT assay.
Neuroprotective effect of thapsigargin
The effect of mefloquine (10 or 80 µM for 5 min), before
and after pretreatment with thapsigargin (4 µM for 5
min), on the viability of rat neurons was assessed as
described above. The degree of neuroprotection afforded
by thapsigargin was basically the extent to which the drug
reversed the decline in absorbance (viability) induced by
mefloquine and was calculated as previously described
[14].
Statistical analyses, data analysis and presentation
For the confocal experiments the data are presented as
mean normalized Fluo-3 fluorescence ± the standard error
of the mean (SEM) and are representative of at least three
replicate experiments. Toxicity and neuroprotection data
are presented as mean (%) viability or raw A540 values (±
SEM) and represent the results of at least three experi-
ments in every case. Samples sizes are outlined in the table
or figure legends. For the toxicity experiments, the signifi-
cance of multiple treatments was assessed using one-way
ANOVA and Dunnett's t-test. For the neuroprotection
experiment, the data were analyzed using a two-way
ANOVA, with a P-value < 0.05 for the interaction between
mefloquine and thapsigargin taken to represent an antag-
onistic effect of the two compounds. Statistical procedures
for the analysis of microarray data are discussed above.
Fifty percent inhibitory or effective concentrations and
95% confidence intervals (IC50 or ED50) for the effects of
mefloquine on neuronal viability and calcium homeosta-
sis were calculated using Prism software.
Results
Effects of 80 µM mefloquine on ER calcium homeostasis
As can be seen from examination of the first peak in Figure
1, mefloquine caused a transient increase in intracellular
calcium levels whereas DMSO did not. Mefloquine also
antagonized the subsequent transient elevation of cyto-
plasmic calcium induced by the addition of thapsigargin
as can be seen from examination of the second series of
peaks in Figure 1. A subsequent addition of glutamate
failed to elicit a calcium response, whereas addition of cal-
cium chloride to the medium did. The antagonisation by
mefloquine of the ER calcium release induced by thapsi-
gargin, a specific inhibitor of the ER calcium pump, sug-
gests that mefloquine mobilizes ER calcium stores.
Glutamate induces the activation of plasma membrane
influx channels, therefore its failure to illicit a calcium
response shows that the external media contained low lev-
els of free calcium. Therefore the elevation of intracellular
calcium cannot be attributed to influx from an external
source. The subsequent ability of the neurons to elicit a
response after restoration of normal levels of extracellular
calcium shows that the neurons selected for the confocal
microscopy experiments remained viable for the duration
of these experiments.
Low-calcium Locke's buffer does not substantially reduce 
neuronal viability
The neurotoxicity of the low calcium Locke's buffer was
investigated over time. As can be seen from Figure 2, sub-
stitution of normal Locke's buffer for one containing no
added calcium results in a loss of neuronal viability (27%
reduction, Welch's test, P < 0.005, n = 8). This solution
was not used for the mefloquine studies because control
experiments showed that glutamate elicited a calcium
response in neurons exposed to this buffer (data not
shown), presumably because the rinsing procedure did
not remove all residual free calcium. We utilized a low
calcium (920 µM) Locke's buffer supplemented with
EGTA (1 mM) for the confocal microscopy experiments.
As can be seen from Figure 2, exposure to this buffer for
10 minutes was required to reduce the viability of the neu-
rons below that induced by treatment of neurons with
Locke's containing no added calcium (one way ANOVA
and Dunnett's test, P < 0.05, n = 44). All mefloquine cal-
cium response experiments were conducted within this
time frame, and care was taken to analyze data only from
neurons that were shown to be viable at the termination
of the experiment (as indicated by the CaCl2-induced cal-
cium response).
Effect of lower mefloquine concentrations on ER calcium 
homeostasis and relationship to time-dependent 
neurotoxicity
We next investigated the effects of lower mefloquine doses
on neuronal ER calcium homeostasis (i.e. in low-calcium
Locke's buffer). At concentrations of at least 30 µM,
mefloquine induced a transient increase in cytosolic cal-
cium levels (Table 1, one-way ANOVA, Dunnett's t-test, P
< 0.05, n = 29). The effect was dose-related, with an ED50
of 66 µM (95% confidence interval, 33 – 130 µM). The
IC50 of mefloquine's effect on neuronal viability after 5
min exposure was 62 (19–204) µM, and the dose
response curves of the two effects are super-imposable
(Figure 3). These data suggest that the two effects may be
related. The IC50s of mefloquine's effect on neuronal via-Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
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bility were 23 (18–28) and 19 (11–32) µM for exposure
times 20 min and 24 h respectively. The concentration-
effect curves are super-imposable. Also, at a concentration
of 50 µM, mefloquine exhibited a greater neurotoxic effect
after 20 min or 24 h exposure as compared to a 5 minute
exposure (one way ANOVA and Dunnett's t-test, P  <
0.0001, n = 12). Therefore, it appears that most of meflo-
quine's neurotoxic effects occur within 20 min of expo-
sure, but cannot be accounted for solely by the disruptive
effect of mefloquine on ER calcium homeostasis. Conse-
quently, we investigated the effect of mefloquine on neu-
ronal calcium homeostasis in calcium-containing media.
Effect of mefloquine on whole cell calcium homeostasis
The effects of mefloquine on neuronal calcium homeosta-
sis in calcium-containing medium were investigated. As
shown in Figure 4, mefloquine (80 µM) caused an imme-
diate and sustained rise in cytoplasmic calcium levels. In
some experiments, this sustained elevation of cytoplasmic
calcium was preceded by a transient rise as observed in
low calcium Locke's (as in Figure 1). The sustained
elevation of cytoplasmic calcium can only be due to entry
from an external source, as it was not observed in the low-
calcium medium.
Thapsigargin antagonizes the disruptive effect of meflo-
quine on calcium homeostasis and protects neurons from 
cellular injury
Pre-treatment with thapsigargin (4 µM) antagonised both
the initial rise in intracellular calcium attributable to the
effect of mefloquine on the ER calcium store, and the sub-
sequent sustained influx of external calcium (Figure 4).
We next investigated the possibility that thapsigargin pre-
treatment might have a protective effect on neurons
exposed to mefloquine. Rat neurons were pretreated with
either thapsigargin (4 µM) or DMSO (0.4%) for 5 min
prior to the addition of DMSO (0.2%) or mefloquine (10
or 80 µM) for 5 min. The drugs were then removed and
incubated in calcium-containing MEM medium for 24 h
prior to viability assessment using the MTT assay. As can
be seen in Figure 5, pretreatment with thapsigargin
reduced the decline in viability (absorbance) induced by
mefloquine by 60%. There was a significant interaction
between thapsigargin and mefloquine, indicating that the
drugs behave antagonistically (two way ANOVA, P  <
0.0001, n = 48).
Mefloquine upregulates the transcription of important ER 
stress response genes
The Rat Genome U34 array was found to contain probe-
sets representing the ER chaperones glucose-regulated
protein (GRP) 78, protein disulfide isomerase, GRP94,
calreticulin and endoplasmic reticulum protein 29
(EPR29), GADD153 and PERK. Mefloquine (80 µM)
upregulated the transcription of four of five ER resident
chaperones, GRP78, PDI, GRP94 and calreticulin,
GADD153 and PERK (one way ANOVA P < 0.05, n = 20,
FC > 1.3, Table 2). Mefloquine induced no transcriptional
changes at 2 µM (24 h) or 10 µM (5 min). Relative tran-
scriptional changes at each concentration for GRP78,
GADD153 and PERK are shown in Figure 6. Mefloquine
induced no significant change in the levels of λ-tubulin
mRNA (Table 2, Figure 6). λ-tubulin was called present by
Affymetrix software in all 20 samples (mean P = 0.00106),
and the mean control (DMSO) AD (± SEM) value was 444
(± 88).
Discussion
There are relatively few studies that have attempted to
address the possibility that a biochemical explanation
may lie behind the neurotoxicity of mefloquine. How-
ever, previous literature suggested that mefloquine might
disrupt ER calcium homeostasis. Firstly, Go and others
[5,6] showed that mefloquine alters calcium flux into and
out of isolated mammalian microsomes obtained from
skeletal muscle and neuronal tissue. Secondly, meflo-
quine has been shown to cause a striking upregulation of
GADD153, a transcription factor selectively modulated
under conditions of ER stress [8]. However, the depletion
of the ER calcium pool on the one hand, and a consequent
induction of an ER stress response have not been shown
to occur simultaneously in intact primary neurons. In the
Table 1: Dose-response effects of mefloquine on elevation of cytosolic calcium levels induced via liberation of the ER store.
Concentration in µM (# of experiments) Relative increase in cytosolic CA2+ due to ER 
calcium release (range)
Magnitude of effect relative to 200 µM 
mefloquine (%)
DMSO (4) 1.0 (1.0–1.0) 0
2 (4) 1.0 (1.0–1.2) 2.4
10 (4) 1.1 (1.0–1.2) 3.6
30 (5) 1.5 (1.2–1.7) 30
60 (4) 1.9 (1.8–2.6) 53
80 (4) 2.5 (2.1–2.9) 74
200 (4) 3.2 (2.6–4.1) 100Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
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present study, utilizing confocal microscopy and Affyme-
trix arrays, we have shown that at least one component of
the neurotoxicity of mefloquine can be attributed to an
effect on the ER calcium store, and that the drug activates
a UPR similar to that induced by agents known to disrupt
ER function.
We employed confocal microscopy as a tool to investigate
the effects of mefloquine on calcium homeostasis. This
approach has an advantage over that employed by Go et
al [6], in that calcium homeostasis can be assessed in real-
time in live, intact neurons. Our data show that, in nomi-
nally calcium free medium, mefloquine induces a transi-
tory elevation of cytoplasmic calcium levels and
antagonizes a similar effect induced by thapsigargin. The
most reasonable interpretation of these data is that meflo-
quine mobilizes a thapsigargin-sensitive calcium pool,
and, since thapsigargin is known to mobilize the ER cal-
cium pool, that this is also the case for mefloquine. The ER
calcium pool can be mobilized in two ways. Firstly, an
Figure 4
Effects of mefloquine on whole cell calcium homeostasis and their antagonisation by thapsigargin. The effects of 
mefloquine on neuronal whole cell calcium homeostasis were investigated using confocal microscopy and Locke's buffer con-
taining physiological calcium levels (2.3 mM). Neurons were loaded with the calcium-sensitive dye Fluo-3 that was replaced 
with normal Locke's buffer after 1 h. Neurons were scanned at 15 s intervals. Mefloquine (MEF80, 80 µM), thapsigargin 
(THAPS, 4 µM) or DMSO (0.4%) were added at scan 13 (as indicated by the first arrow). Subsequently (second arrow at scan 
28), DMSO (0.2%) or mefloquine (80 µM) were added. Mefloquine (but not DMSO) caused an immediate and sustained rise in 
the cytosolic calcium concentration. This elevation is due to an influx across the plasma membrane as it was not observed in 
neurons bathed in low calcium Locke's buffer. The effect was antagonized by prior treatment with thapsigargin. As this agent is 
a specific inhibitor of the ER calcium pump, the data suggest that the effects of mefloquine on calcium homeostasis are medi-
ated at the level of the ER in rat neurons.
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inhibitory effect of an ER-active agent (e.g. thapsigargin)
on the ER Ca2+-ATPase results in a decrease in the rate of
calcium influx across the ER membrane. As a consequence
of a passive leak of calcium ions across the ER membrane
into the cytoplasm, the store becomes depleted and a tran-
sient elevation in the cytoplasmic calcium concentration
occurs. Alternatively, some ER-active agents (e.g. ryanod-
ine) deplete the calcium store by activating calcium
release channels. Either of these effects could account for
our observations.
Compromised ER function (induced by numerous stres-
sors including depletion of ER calcium stores) may lead to
the accumulation of unfolded proteins in the ER [11].
These events may trigger the UPR, in which the transcrip-
tion of genes encoding ER-resident chaperones is upregu-
lated. The ability of mefloquine to upregulate the
transcription of PDI, GRP78, GRP94 and calreticulin is
consistent with this hypothesis. Triggering of the UPR also
results in the suppression of global protein synthesis, as
PERK is activated and phosphorylates EIK2α, which can
only interact with the appropriate ribosomal binding sites
in an unphosphorylated state [11,12]. While the upregu-
lated transcription of PERK is not required for its activa-
tion, it's over expression can lead to the enhanced
phosphorylation (and therefore inactivity) of EIK2α [16].
Therefore, its up-regulation by mefloquine supports the
hypothesis that the drug triggers an UPR. The third com-
Figure 5
Effects of mefloquine and thapsigargin treatment on viability of rat neurons in vitro. A: The effect of mefloquine 
(Mef, 10 or 80 µM for 5 min), before and after pretreatment with thapsigargin (Thaps, 1 µM or DMSO, 0.4% for 5 min), on the 
viability of rat neurons was assessed using the MTT assay. Data shown are from eight replicate experiments. There was a sig-
nificant interaction between mefloquine and thapsigargin (two way ANOVA, P < 0.01, n = 48). Thapsigargin had a neuroprotec-
tive effect against the toxic action of mefloquine, as indicated by the partial prevention (by 60%) of the reduction in viability 
(A540 units) caused by mefloquine.
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ponent to the UPR cascade is an induction of the ER tran-
scription factor GADD153 [11,12], an effect also observed
after mefloquine treatment. Thus it appears that meflo-
quine induces an UPR similar to that induced by agents
(e.g. thapsigargin) known to cause ER stress [8].
The effects of mefloquine on ER calcium homeostasis
have been examined previously [5,6]. In experiments with
isolated rabbit skeletal muscle microsomes, mefloquine
was found to inhibit the uptake of calcium, with an IC50
of approximately 43 µM [6]. This effect was exacerbated
by treatment with thapsigargin, a specific inhibitor of the
ER calcium pump [6]. Further, the rate of ATP hydrolysis
by the ER Ca2+-ATPase was reduced in the presence of
mefloquine (Ki of = 53 µM). These authors concluded that
the ER calcium pump might be a target of mefloquine. As
discussed above, our own data are also consistent with
such a mechanism. The observation by Go et al. [6], that
the effects of mefloquine and thapsigargin on microsomal
calcium uptake are synergistic, might seem at first to con-
tradict ours. However, it should be pointed out that in our
study, we treated neurons with these two agents
sequentially, so that, in effect, one of the agents was acting
on a depleted ER calcium pool. Under the conditions
employed in our study, it is not surprising that meflo-
quine antagonized the effect of thapsigargin.
Figure 6
Effects of mefloquine on the transcription of ER stress response genes. Changes in the mRNA levels of tubulin, 
GADD153, GRP78 and PERK induced in rat neurons after exposure to mefloquine (5 min treatment followed by 24 h wash-
out) were quantitated using Affymetrix U34 Rat Genome arrays. Mefloquine (80 µM) upregulated the transcription of 
GADD153, GRP78 and PERK but not tubulin (one way ANOVA, P < 0.05, n = 20), suggesting that the drug induces an ER 
stress response at this concentration.
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Li et al [5] also found that mefloquine inhibited calcium
uptake into isolated microsomes from dog brain neurons
– presumably via the same mechanism – although the
drug was much less potent (IC50 of 272 µM) than we are
reporting it to be. We observed an approximately four-
fold more potent effect of mefloquine on ER calcium
homeostasis in rat neurons (IC50 of 66 µM). It would be
tempting to speculate that, because mefloquine's effects
on rat neuronal ER calcium homeostasis were more
potent than that for dog-brain microsomes, there might
exist a species difference in sensitivity to the drug.
However, this would be premature, since the two studies
have employed markedly different experimental systems
to observe similar phenomena. Li et al. also observed that
mefloquine inhibited IP3-induced calcium release from
isolated dog brain microsomes [5]. Our results do not pre-
clude such a role for mefloquine in neuronal cells,
although it would not have been possible to observe such
an effect in the present study, since we investigated only
the spontaneous action of mefloquine on ER calcium
homeostasis.
Mefloquine's disruption of ER calcium homeostasis may
contribute to the acute neurotoxicity of the drug, since the
concentration-response for these effects are superimposa-
ble over the same time frame (5 minutes). However, the
toxicity of the drug is somewhat time-dependent, since
the magnitude of its effect is greater after twenty minutes
exposure as compared to five minutes. We also
investigated mefloquine's effects in calcium-containing
medium and found that the drug induces a sustained sec-
ondary rise in cytoplasmic calcium originating from an
external source. Thapsigargin blocked both the initial and
secondary rises in cytoplasmic calcium induced by meflo-
quine and partially reversed the neurotoxicity of the drug.
These observations are suggestive of two things. Firstly,
the trigger for the sustained elevation in cytoplasmic cal-
cium may occur at the level of the ER, and secondly, this
effect may also contribute substantially to the
neurotoxicity of mefloquine. However, the molecular
basis for these two events is unclear. It is possible that
mefloquine induces store-mediated capacitative calcium
entry [see reference [17]]. However, it is unclear why thap-
sigargin, which also depletes the ER calcium store, would
not produce a similar effect. Our laboratory is currently
investigating the possibility that known inhibitors of
store-mediated calcium entry (e.g. non hydrolysable GTP
analogs and SKF96365) might also block the effects of
mefloquine.
Mefloquine use has been associated with two broad
classes of neurological disorders: (i) central and periph-
eral nervous system disorders including headache, dizzi-
ness, vertigo and seizures and (ii) psychiatric events
including insomnia, anxiety, affective and major disor-
ders [2]. It is well known and has been accepted for some
time that prolonged disruptions in Ca2+ homeostasis can
result in impairment of neuronal function and cell death
[18,19]. Impairment or loss of neurons in specific regions
of the brain might be manifested in symptoms reported to
have occurred in patients treated with mefloquine. For
example, the vertigo reported by some patients might be
attributable to neuronal death in the inferior cerebellum
[20], whereas symptoms of fear/anxiety might arise as a
consequence of the death of neurons in the amygdala
[21]. Mefloquine-induced neurotoxicity in the limbic sys-
tem might be responsible for reported disturbances in
emotion [22].
Table 2: Changes in the transcriptional modulation of ER stress response genes induced by mefloquine in rat neurons.
Protein Genbank 
accession
ANOVA P Fold-change at: ANOVA P < 0.05 and FC > 1.3 at 80 µM?
2 µM1 0   µM 80 µM
ER chaperones
GRP78 S63521 0.0186 1.0 1.0 2.6 YES
PDI X02918 0.000219 1.0 1.0 1.7 YES
GRP94 S69315 0.004307 1.1 1.0 0.8 NO
GRP94 S69316 0.000165 1.0 1.0 2.2 YES
ERP29 U63482 0.23012 0.8 0.9 1.3 NO
Calreticulin D78308 0.0062 1.0 1.0 1.5 YES
ER-relevant transcription factors
GADD153 U30186 0.00207 1.0 1.0 3.0 YES
EIF2α kinases
PEK/PERK AF096835 0.000587 0.7 0.9 4.6 YES
Controls
Tubulin AB015946 0.926 1.2 1.0 1.0 NOMalaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/14
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Mefloquine accumulates to plasma concentrations of 3.8
and 2.1–23 µM after administration at prophylactic dose
and therapeutic dosing respectively [3,4]. Therefore, only
at the time of peak plasma concentrations in a few
patients, do mefloquine plasma concentrations approach
the threshold necessary (> 10 µM) to induce any of the
effects observed in the present study. However, in human
post-mortem cases, mefloquine has been found to accu-
mulate in the brain relative to plasma by as much as 30-
fold, with absolute, equivalent concentrations exceeding
50 µM (Table 3). These observations have been confirmed
in rats, where the accumulation was found to be 12.5-fold
with absolute, equivalent concentrations exceeding 90
µM (Table 3). Thus, mefloquine apparently crosses the
blood-brain barrier and accumulates to sufficient levels to
include those concentrations found to disrupt neuronal
calcium homeostasis and ER function in vitro. The possi-
bility that a disruption of neuronal calcium homeostasis
or ER function may be responsible, at least in part, for the
clinical neurotoxicity of mefloquine is worthy of further
investigation.
Conclusion
Mefloquine was found to disrupt calcium homeostasis in
rat neurons by mobilizing the ER calcium pool and induc-
ing a sustained elevation of cytoplasmic calcium
originating from an external source. Mefloquine also
induced a characteristic ER stress response. The effects
were observed at physiologically relevant concentrations
and may contribute to the acute neurotoxicity of the drug
in vitro.
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